NeOnc Technologies (NTHI) said Monday it expects full enrollment in a phase 2a trial for its therapeutic candidate NEO100-01 by September, with just six patients remaining to reach the 25-patient target.

The trial is evaluating NEO100, which is intended for the treatment of malignant gliomas, particularly IDH1 mutant Grade III and IV astrocytomas. The read-out for the trial's data is expected early next year, the company said.

The drug candidate has been granted orphan drug and fast-track status by the US Food and Drug Administration, according to the company.

Price: 8.64, Change: -0.27, Percent Change: -3.03